Platinum Priority – Review – Bladder CancerEditorial by Maurizio A. Brausi on pp. 242–243 of this issueEpidemiology and Risk Factors of Urothelial Bladder Cancer
Introduction
Urothelial bladder cancer (UBC) is the 7th most common cancer in men and the 17th most common in women worldwide. UBC is more common in developed countries and is the fourth and ninth most common cancer in men and women, respectively in the Western world [1]. This frequency, coupled with the relapsing nature of UBC, means that UBC poses an enormous burden on health care systems [2]. Approximately 75% of newly diagnosed UBCs are noninvasive and have a high rate of recurrence and progression despite local therapy. The remaining 25% of newly diagnosed UBCs present with muscle invasion and need either radical surgery or radiotherapy but often still have poor outcomes despite systemic therapy [3], [4]. Several reviews have focused on the clinical challenges in managing bladder cancer (BCa) [5], [6], [7]. In this work we will elucidate epidemiologic aspects of UBC and focus on factors that increase the incidence of urothelial carcinoma of the bladder, since this represents the most common histology [3], [4].
Section snippets
Evidence acquisition
In preparation for this review, a literature search in English was performed using PubMed between February and May 2012 for the keywords bladder cancer, incidence, prevalence, risk, risk factor, and hazard, and one keyword for each risk factor described in the literature retrieved. More than 5000 publications were retrieved. Relevant papers were preselected by two authors (M.B. and Y.L.), and the list of papers to be included was edited by all of the authors.
Epidemiology of urothelial bladder cancer: incidence, prevalence, and mortality
Although exact numbers for cancer incidence and outcome are difficult to obtain and inherently delayed, the International Agency for Research on Cancer provides statistics and estimates. Details are depicted in Fig. 1, Fig. 2. The incidence of UBC ranks it as the sixth most common cancer and as the fourth most common if UBC stage Ta is included [1]. The variations noted can partly be attributed to different methodology, mainly the inclusion of UBC stage Ta or carcinoma in situ in different
Conclusions
UBC is a common malignancy. Most data available are based on retrospective analyses, and each risk factor for UBC has to be seen in light of genetic–environmental interactions to better evaluate its impact. It is evident, however, that UBC will remain frequent because of the ongoing high prevalence of smoking, which represents its main risk factor. The importance of primary prevention needs to be stressed, and smoking cessation programs should be encouraged and supported.
References (51)
- et al.
EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update
Eur Urol
(2011) - et al.
Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines
Eur Urol
(2011) How well can you actually predict which non-muscle-invasive bladder cancer patients will progress?
Eur Urol
(2011)- et al.
Multimodality treatment versus radical cystectomy: bladder sparing at cost of life?
Eur Urol
(2012) - et al.
Maximizing cure for muscle-invasive bladder cancer: integration of surgery and chemotherapy
Eur Urol
(2011) - et al.
Trends in mortality from urologic cancers in Europe, 1970-2008
Eur Urol
(2011) - et al.
Potential years of life lost due to urogenital cancer in the United States: trends from 1972 to 2006 based on data from the SEER database
J Urol
(2012) - et al.
Select screening in a specific high-risk population of patients suggests a stage migration toward detection of non-muscle-invasive bladder cancer
Eur Urol
(2011) - et al.
Genetic susceptibility to distinct bladder cancer subphenotypes
Eur Urol
(2010) - et al.
Effects of N-acetyl transferase 1 and 2 polymorphisms on bladder cancer risk in Caucasians
Mutat Res
(2005)
Smoking status is a risk factor for recurrence after transurethral resection of non-muscle-invasive bladder cancer
Eur Urol
Alcohol drinking and bladder cancer risk: a meta-analysis
Ann Oncol
Fluid intake and the risk of tumor recurrence in patients with superficial bladder cancer
J Urol
Long-term use of supplemental vitamins and minerals does not reduce the risk of urothelial cell carcinoma of the bladder in the VITamins and Lifestyle Study
J Urol
Evaluation of vitamin E and selenium supplementation for the prevention of bladder cancer in SWOG coordinated SELECT
J Urol
Long-term impact of arsenic in drinking water on bladder cancer health care and mortality rates 20 years after end of exposure
J Urol
Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guérin
Eur Urol
Ethnic differences in bladder cancer survival
Urology
Economic aspects of bladder cancer: what are the benefits and costs?
World J Urol
The present and future burden of urinary bladder cancer in the world
World J Urol
Cancer incidence in the United Kingdom: projections to the year 2030
Br J Cancer
A sequence variant at 4p16.3 confers susceptibility to urinary bladder cancer
Nat Genet
Sequence variant on 8q24 confers susceptibility to urinary bladder cancer
Nat Genet
Cited by (1561)
European cancer mortality predictions for the year 2024 with focus on colorectal cancer
2024, Annals of OncologyPatient reported treatment burden and attitudes towards in-home intravesical therapy among patients with bladder cancer
2024, Urologic Oncology: Seminars and Original InvestigationsIntra-arterial chemotherapy plus BCG, a promising combination adjuvant treatment for high-risk NMIBC
2024, Urologic Oncology: Seminars and Original InvestigationsInhibition of aldo-keto reductase 1C3 overcomes gemcitabine/cisplatin resistance in bladder cancer
2024, Chemico-Biological Interactions